NCT02323906 - Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 16, 2015

Primary Completion Date

December 21, 2016

Study Completion Date

December 21, 2016

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG

CC-122

Investigational new drug

DRUG

Sorafenib

Kinase inhibitor

Trial Locations (8)

Greenville Hospital System, Greenville

Moffitt Cancer Center, Tampa

Henry Ford Hospital, Detroit

University of Utah Huntsman Cancer Institute, Salt Lake City

University of California San Francisco, San Francisco

Seattle Cancer Care Alliance, Seattle

University of Florida College of Med, Gainesville

Indiana University Cancer Center, Indianapolis